Inflammatory Bowel Disease in South Eastern Norway (IBSENIII)

March 3, 2020 updated by: Marte Lie Høivik, Oslo University Hospital

Inflammatory Bowel Disease in South Eastern Norway (IBSEN III). Clinical Epidemiology, Diagnostic and Prognostic Factors in Inflammatory Bowel Disease.

The IBSEN III study will investigate the incidence of inflammatory bowel disease in South Eastern Norway and describe the clinical course of the disease. The investigators will map newly diagnosed and treatment naive IBD patients at various levels (epidemiological, clinical, psychosocial and nutritional as well as immunological, genetic, epigenetic and microbial) as a basis to improve targeted and individualized treatment and care. The investigators will include incident IBD patients at all local- and university hospitals in the South Eastern Health Region in 2016-2018 and follow-up prospectively for five years. The investigators will use standardized and validated registration methods allowing comparability with previous national and international IBD cohorts, link data to national health registries and collect blood, feces and biopsies for bio banking.

Study Overview

Study Type

Observational

Enrollment (Actual)

2286

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Oslo, Norway, 0871
        • Oslo University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 100 years (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult and pediatric patients untreated and newly diagnosed with inflammatory bowel disease i.e ulcerative colitis or Crohns disease as well as non-IBD Controls.

Description

Inclusion Criteria:

Ulcerative colitis:

Diagnostic criteria (at least three out of four criteria present):

  1. A history of diarrhea and/or pus in stools for more than 4weeks or repeated episodes.
  2. Macroscopic appearance at endoscopy of continuous mucosal inflammation affecting the rectum in continuity with some or the entire colon.
  3. Microscopic features on biopsy compatible with UC,
  4. No suspicion of CD on small bowel X-ray, ileocolonoscopy or biopsy.

Crohn's disease:

Diagnostic criteria (at least two of four criteria present):

  1. History of abdominal pain, weight loss and/or diarrhea for more than three months.
  2. Characteristic endoscopic findings of ulceration (aphthous lesions, snail track ulceration) or cobble stoning or radiological features of stricture or cobble stoning.
  3. Histopathology consistent with Crohn's disease (epitheloid granuloma of Langerhans type or transmural discontinuous focal or patchy inflammation).
  4. Fistula and/or abscess in relation to affected bowel segments.

Inflammatory bowel disease, type unclassified (IBDU) :

Patients with evidence on clinical and endoscopic grounds for chronic inflammatory bowel disease affecting the colon, without small bowel involvement, and no definitive histological or other evidence to favor either CD or UC.

Pediatric patients:

Will be diagnosed according to the Porto-criteria and defined as:

Pediatric onset IBD ≤ 16 years Early Onset IBD (EOIBD) < 10 years Very Early Onset IBD (VEOIBD) < 6 years Infantile (and toddler) IBD < 2 years Neonatal IBD < 28 days

Exclusion criteria:

  • Other causes of acute or chronic bowel inflammation must be excluded, i.e. infectious colitis, radiation colitis, diversion colitis, solitary rectal ulcer syndrome, graft versus host disease, diverticular colitis, medication associated colitis, ischemic colitis, microscopic colitis, enema associated colitis.
  • Refusal or not able to give informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients newly diagnosed with IBD
Symptomatic non IBD-controls
Patients referred with symptoms suspicious of IBD, but who, after examination, are found not to have the diagnosis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evidence for ulcerative colitis, Crohn's disease or indeterminate colitis based on specific clinical, endoscopic, histological and radiological criteria
Time Frame: At baseline
Diagnosis according to the Lennard Jones Criteria for the diagnosis of inflammatory bowel disease
At baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in IBD diagnosis between baseline and one year follow-up
Time Frame: 1 year (+/-3 months)
Change in diagnosis based on specified clinical, endoscopic, histological and radiological criteria
1 year (+/-3 months)
Change in IBD diagnosis between one year and five year follow-up
Time Frame: 5 year (+/-3 months)
Change in diagnosis based on specified clinical, endoscopic, histological and radiological criteria
5 year (+/-3 months)
Change in disease classification (montreal Classification) between baseline and one year follow-up.
Time Frame: 1 year (+/-3 months)
Change in disease extension and severity as defined in the Montreal classification system for IBD
1 year (+/-3 months)
Change in disease classification (montreal Classification) between one and five year follow-up
Time Frame: 5 year (+/-3 months)
Change in disease extension and severity as defined in the Montreal classification system for IBD
5 year (+/-3 months)
IBD related bowel surgery
Time Frame: 1 year (+/-3 months)
Bowel surgery for any IBD related condition
1 year (+/-3 months)
IBD related bowel surgery
Time Frame: 5 year (+/-3 months)
Bowel surgery for any IBD related condition
5 year (+/-3 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2017

Primary Completion (ACTUAL)

December 31, 2019

Study Completion (ACTUAL)

December 31, 2019

Study Registration Dates

First Submitted

February 15, 2016

First Submitted That Met QC Criteria

March 30, 2016

First Posted (ESTIMATE)

April 5, 2016

Study Record Updates

Last Update Posted (ACTUAL)

March 5, 2020

Last Update Submitted That Met QC Criteria

March 3, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Crohn Disease

3
Subscribe